Recent Advances in HIV-1 Gag Inhibitor Design and Development
Open accessThe DOI matches its Crossref record; 150 of the 153 references it cites were found in a registry or an index.
Abstract
Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation. However, resistance mutations and the accumulation of severe side effects associated with cART remain enormous challenges that need to be addressed with the continual design and redesign of anti-HIV drugs. In this review, we focus on the importance of the HIV-1 Gag polyprotein as the master coordinator of HIV-1 assembly and maturation and as an emerging drug target. Due to its multiple roles in the HIV-1 life cycle, the individual Gag domains are attractive but also challenging targets for inhibitor design. However, recent encouraging developments in targeting the Gag domains such as the capsid protein with highly potent and potentially long-acting inhibitors, as well as the exploration and successful targeting of challenging HIV-1 proteins such as the matrix protein, have demonstrated the therapeutic viability of this important protein. Such Gag-directed inhibitors have great potential for combating the AIDS pandemic and to be useful tools to dissect HIV-1 biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Surface conservation of the HIV-1 Gag polyprotein and inhibitor target sites. Alignment of 9547 HIV-1 Gag sequences were retrieved from the HIV Los Alamos database (www.hiv.lanl.gov). Sequences were aligned against the HxBc2 reference. Conservation analysis was performed using the ConSurf server [10]. Structures of the HIV-1 Gag domains with PDB entries: matrix, 2H3Z; capsid, 6ES8; sp2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. Orange boxes represent target sites for inhibitor binding highlighted in this review. Low conservation in light cyan to high conservation in dark purple.Gag’s constituent proteins act at different points in the viral life cycle. MA binds specifically to phosphoinositide 4,5-bisphosphate (PI [4,5]P2) and specific phospholipids on the plasma membrane, triggering the exposure of an attached myristoyl (myr) chain and directing Gag to the membrane. This membrane interaction is required for the correct incorporation of the viral envelope protein (Env) into the budding virus [11,12,13,14]. In the late stages of the replication cycle, CA is responsible for the assembly of Gag at the plasma membrane by providing intermolecular contact sites for Gag oligomerization at the plasma membrane [15,16]. In the early stages of replication, CA disassembly regulates the process of reverse transcription, and its engagement of cellular transportins and nuclear pore components facilitate the import of the viral pre-integration complex into the nucleus, where integration takes place [17]. NC functions as a nucleic acid chaperone at multiple steps in the HIV-1 replication cycle, and it’s overall positively charged character and two zinc-finger motifs allow it to interact with viral genomic RNA via the RNA packaging signal and thereby facilitate virion assembly [18,19,20,21]. Finally, the p6 domain (late domain) recruits the endosomal sorting complex required for transport (ESCRT) machinery to promote virus budding and final release [22]. Two spacer peptides (SP1 and SP2) flanking the NC domain regulate the kinetics of Gag maturation, and SP1 also provides, as part of the C-terminus of CA, another Gag-Gag multimerization interface [23,24]. Because Gag functions in so many different aspects of viral infection and replication, Gag inhibitors have the potential to exert their effects in both early and late stages of the replication cycle, making this polyprotein a particularly attractive target for the development of new therapeutics.](https://figures.cochat.ai/paper-figures/fa72841e53e64979b7a5c91ac99c660f/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-2.jpg)

![Figure 4 MA inhibitors targeting the PI[4,5]P2 binding site. (A) The NMR structure of MA with its myristic acid (in yellow) buried in a hydrophobic groove at the N-terminus (PDB code: 2H3I). (B) The NMR structure of MA bound to di-C4-PI[4,5]P2 displacing the myristic acid (PDB code: 2H3Z). (C) Docking model of compound 7 bound to MA and displacing di-C4-PI[4,5]P2. In red are the residues highlighted that are involved in di-C4-PI[4,5]P2 binding.](https://figures.cochat.ai/paper-figures/08e949ba452943f1a7098f286d16c3e7/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-4.jpg)







![Figure 12 Zinc ejecting mechanisms: Class 1) Electrophilic attack of the zinc fingers. The nucleophilic attack of the cysteine 39 results in the formation of a thioester by SAMTs. This covalent linkage stimulates the reaction of additional reactants with the other Cys residues of the same motif and leads to reduction in Zn2+ affinity of the zinc finger and finally zinc ejection and NC unfolding [131]. Class 2) Zinc chelation by the two carbonyl oxygens of the ester from NVO38 [133]. Class 3) Covalent binding of Cys residues by platinum (Pt) as represented by trans-chlorobispyridine(9-ethylguanine)platinum(II) [137]. Cys (N) and Cys (C) represent N-terminal and C-terminal cysteines in the zinc finger.](https://figures.cochat.ai/paper-figures/6e7a2b9588af4184aa04e818cc6866d6/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-12.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys
Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P., & Sodroski, J. (2004) · Nature · doi:10.1038/nature02343 · Cited by 1,816
Origins of HIV and the AIDS Pandemic
Sharp, P. M., & Hahn, B. H. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006841 · Cited by 1,496
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331 · cited 1×
“Long-term cART therapy also leads to side effects and age-related comorbidities such as diabetes, cardiovascular, renal, and bone diseases and can result in a reduced life expectancy of HIV-1 infected patients [7,8].”
BackgroundCyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses
Gao, D., Wu, J., Wu, Y.-T., Du, F., Aroh, C., Yan, N., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1240933 · Cited by 992
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
HIV-1 assembly, budding, and maturation
Sundquist, W. I., & Krausslich, H.-G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006924 · Cited by 814
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V., & Goff, S. P. (1993) · Cell · doi:10.1016/0092-8674(93)90637-6 · Cited by 802
Martin-Serrano, J., Zang, T., & Bieniasz, P. D. (2001) · Nature Medicine · doi:10.1038/nm1201-1313 · Cited by 710
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1
Sayah, D. M., Sokolskaja, E., Berthoux, L., & Luban, J. (2004) · Nature · doi:10.1038/nature02777 · Cited by 662 · cited 1×
“Host cell restriction factors have also been shown to recognize CA such as MxB [89,90], TRIM5a [91] and TRIMCyp [92], which accelerates uncoating and release of viral DNA, which can be sensed by other restriction factors such as the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS) [93].”
BackgroundHIV-1 assembly, release and maturation
Freed, E. O. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3490 · Cited by 654 · cited 1×
“Gag contains the matrix (MA), capsid (CA), and nucleocapsid (NC) proteins, in addition to a small p6 domain and two spacer peptides (Figure 1) [9].”
BackgroundTsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 Gag
VerPlank, L., Bouamr, F., LaGrassa, T. J., Agresta, B., Kikonyogo, A., Leis, J., & Carter, C. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131059198 · Cited by 584
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
Goujon, C., Moncorgé, O., Bauby, H., Doyle, T., Ward, C. C., Schaller, T., Hué, S., Barclay, W. S., Schulz, R., & Malim, M. H. (2013) · Nature · doi:10.1038/nature12542 · Cited by 583
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane
Ono, A., Ablan, S. D., Lockett, S. J., Nagashima, K., & Freed, E. O. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405596101 · Cited by 553
Virus budding and the ESCRT pathway
Votteler, J., & Sundquist, W. I. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.08.012 · Cited by 547
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly
Saad, J. S., Miller, J., Tai, J., Kim, A., Ghanam, R. H., & Summers, M. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602818103 · Cited by 545 · cited 2×
“Binding to PI[4,5]P2 facilitates the exposure of the buried/folded myr moiety and promotes oligomerization at the PM (Figure 4A,B) [12,50,51].”
BackgroundForshey, B. M., von Schwedler, U., Sundquist, W. I., & Aiken, C. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5667-5677.2002 · Cited by 522
MX2 is an interferon-induced inhibitor of HIV-1 infection
Kane, M., Yadav, S. S., Bitzegeio, J., Kutluay, S. B., Zang, T., Wilson, S. J., Schoggins, J. W., Rice, C. M., Yamashita, M., Hatziioannou, T., et al. (2013) · Nature · doi:10.1038/nature12653 · Cited by 509
The structural biology of HIV assembly
Ganser-Pornillos, B. K., Yeager, M., & Sundquist, W. I. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.02.001 · Cited by 503
HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation
Checkley, M. A., Luttge, B. G., & Freed, E. O. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.042 · Cited by 479
Hill, C. P., Worthylake, D., Bancroft, D. P., Christensen, A. M., & Sundquist, W. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3099 · Cited by 473
Structure of the Amino-Terminal Core Domain of the HIV-1 Capsid Protein
Gitti, R. K., Lee, B. M., Walker, J., Summers, M. F., Yoo, S., & Sundquist, W. I. (1996) · Science · doi:10.1126/science.273.5272.231 · Cited by 459
Projected life expectancy of people with HIV according to timing of diagnosis
Nakagawa, F., Lodwick, R. K., Smith, C. J., Smith, R., Cambiano, V., Lundgren, J. D., Delpech, V., & Phillips, A. N. (2012) · AIDS · doi:10.1097/qad.0b013e32834dcec9 · Cited by 443
Zhu, P., Chertova, E., Bess, J., Lifson, J. D., Arthur, L. O., Liu, J., Taylor, K. A., & Roux, K. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2634931100 · Cited by 431
Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D. E., Orenstein, J. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234683100 · Cited by 426
Rein, A., Henderson, L. E., & Levin, J. G. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01256-0 · Cited by 394
Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA
Gorelick, R. J., Nigida, S. M., Bess, J. W., Arthur, L. O., Henderson, L. E., & Rein, A. (1990) · Journal of Virology · doi:10.1128/jvi.64.7.3207-3211.1990 · Cited by 386
Structure and assembly of immature HIV
Briggs, J. A. G., Riches, J. D., Glass, B., Bartonova, V., Zanetti, G., & Kräusslich, H.-G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903535106 · Cited by 368 · cited 1×
“During viral maturation (late-phase) and translocation of the immature Gag precursor (Pr55Gag) to host cell membranes, CA-dependent hexagonal lattice structures can be observed [79,80].”
BackgroundLevin, J. G., Guo, J., Rouzina, & Musier‐Forsyth, K. (2005) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(05)80006-6 · Cited by 367
Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly
Jouvenet, N., Neil, S. J. D., Bess, C., Johnson, M. C., Virgen, C. A., Simon, S. M., & Bieniasz, P. D. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040435 · Cited by 357
Current status and prospects of HIV treatment
Cihlar, T., & Fordyce, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.004 · Cited by 337
Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., & Kräusslich, H.-G. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2846-2854.1998 · Cited by 336 · cited 1×
“Immature virus particles are non-infectious and have a hexameric Gag lattice without the characteristic conical core architecture [15,25].”
BackgroundStructure of Full-Length HIV-1 CA: A Model for the Mature Capsid Lattice
Ganser-Pornillos, B. K., Cheng, A., & Yeager, M. (2007) · Cell · doi:10.1016/j.cell.2007.08.018 · Cited by 321 · cited 1×
“Hexamers and pentamers are stabilized by NTD-NTD interactions and intermolecular NTD-CTD interactions, while the extended hexameric lattice is connected via CTD-CTD interactions [82].”
BackgroundEntropic switch regulates myristate exposure in the HIV-1 matrix protein
Tang, C., Loeliger, E., Luncsford, P., Kinde, I., Beckett, D., & Summers, M. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305665101 · Cited by 320
Crystal structure of dimeric HIV-1 capsid protein
Momany, C., Kovari, L. C., Prongay, A. J., Keller, W., Gitti, R. K., Lee, B. M., Gorbalenya, A. E., Tong, L., McClure, J., Ehrlich, L. S., et al. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0996-763 · Cited by 319
Freed, E. O., & Martin, M. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1984-1989.1995 · Cited by 313
HIV‐1 DNA Flap formation promotes uncoating of the pre‐integration complex at the nuclear pore
Arhel, N. J., Souquere‐Besse, S., Munier, S., Souque, P., Guadagnini, S., Rutherford, S., Prévost, M., Allen, T. D., & Charneau, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601740 · Cited by 295
HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention
Blair, W. S., Pickford, C., Irving, S. L., Brown, D. G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., Jackson, L., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001220 · Cited by 291
Price, A. J., Jacques, D. A., McEwan, W. A., Fletcher, A. J., Essig, S., Chin, J. W., Halambage, U. D., Aiken, C., & James, L. C. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004459 · Cited by 284
Dorfman, T., Luban, J., Goff, S. P., Haseltine, W. A., & Göttlinger, H. G. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.6159-6169.1993 · Cited by 279
The structure and flexibility of conical HIV-1 capsids determined within intact virions
Mattei, S., Glass, B., Hagen, W. J. H., Kräusslich, H.-G., & Briggs, J. A. G. (2016) · Science · doi:10.1126/science.aah4972 · Cited by 278
Chukkapalli, V., Hogue, I. B., Boyko, V., Hu, W.-S., & Ono, A. (2008) · Journal of Virology · doi:10.1128/jvi.01614-07 · Cited by 268
Structural basis of HIV-1 capsid recognition by PF74 and CPSF6
Bhattacharya, A., Alam, S. L., Fricke, T., Zadrozny, K., Sedzicki, J., Taylor, A. B., Demeler, B., Pornillos, O., Ganser-Pornillos, B. K., Diaz-Griffero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419945112 · Cited by 266
Structural Determinants and Mechanism of HIV-1 Genome Packaging
Lu, K., Heng, X., & Summers, M. F. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.029 · Cited by 263
Murakami, T., & Freed, E. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.343 · Cited by 252
Shi, J., Zhou, J., Shah, V. B., Aiken, C., & Whitby, K. (2011) · Journal of Virology · doi:10.1128/jvi.01406-10 · Cited by 243
A conformational switch controlling HIV-1 morphogenesis
Gross, I. (2000) · The EMBO Journal · doi:10.1093/emboj/19.1.103 · Cited by 241
Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS
Rice, W. G., Supko, J. G., Malspeis, L., Buckheit, R. W., Clanton, D., Bu, M., Graham, L., Schaeffer, C. A., Turpin, J. A., Domagala, J., et al. (1995) · Science · doi:10.1126/science.270.5239.1194 · Cited by 236
Chukkapalli, V., Oh, S. J., & Ono, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908661107 · Cited by 229 · cited 2×
“The basic patch also has nucleic acid binding properties, and it is thought that the interplay between lipid and RNA binding is critical for a specific interaction with only the plasma membrane [11,48].”
BackgroundA peptide inhibitor of HIV-1 assembly in vitro
Sticht, J., Humbert, M., Findlow, S., Bodem, J., Müller, B., Dietrich, U., Werner, J., & Kräusslich, H.-G. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb964 · Cited by 224
HIV Gag polyprotein: processing and early viral particle assembly
Bell, N. M., & Lever, A. M. L. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2012.11.006 · Cited by 222
Antiviral Inhibition of the HIV-1 Capsid Protein
Tang, C., Loeliger, E., Kinde, I., Kyere, S., Mayo, K., Barklis, E., Sun, Y., Huang, M., & Summers, M. F. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00289-4 · Cited by 218
A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor
Zhang, H., Zhao, Q., Bhattacharya, S., Waheed, A. A., Tong, X., Hong, A., Heck, S., Curreli, F., Goger, M., Cowburn, D., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.066 · Cited by 215
The Molecular Architecture of HIV
Briggs, J. A. G., & Kräusslich, H.-G. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.021 · Cited by 208
Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds
Rice, W. G., Schaeffer, C. A., Harten, B., Villinger, F., South, T. L., Summers, M. F., Henderson, L. E., Bess, J. W., Arthur, L. O., McDougal, J. S., et al. (1993) · Nature · doi:10.1038/361473a0 · Cited by 200
Extreme Genetic Fragility of the HIV-1 Capsid
Rihn, S. J., Wilson, S. J., Loman, N. J., Alim, M., Bakker, S. E., Bhella, D., Gifford, R. J., Rixon, F. J., & Bieniasz, P. D. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003461 · Cited by 194
Crystal structure of SIV matrix antigen and implications for virus assembly
Rao, Z., Belyaev, A. S., Fry, E., Roy, P., Jones, I. M., & Stuart, D. I. (1995) · Nature · doi:10.1038/378743a0 · Cited by 183
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription
Levin, J. G., Mitra, M., Mascarenhas, A., & Musier-Forsyth, K. (2010) · RNA Biology · doi:10.4161/rna.7.6.14115 · Cited by 181
Flexible Nature and Specific Functions of the HIV-1 Nucleocapsid Protein
Darlix, J.-L., Godet, J., Ivanyi-Nagy, R., Fossé, P., Mauffret, O., & Mély, Y. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.037 · Cited by 159
Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein
Kelly, B. N., Kyere, S. K., Kinde, I., Tang, C., Howard, B. R., Robinson, H. H., Sundquist, W. I., Summers, M. F., & Hill, C. P. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.07.070 · Cited by 159
Mammano, F., Kondo, E., Sodroski, J., Bukovsky, A., & Göttlinger, H. G. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3824-3830.1995 · Cited by 158
Yant, S. R., Mulato, A., Hansen, D., Tse, W. C., Niedziela-Majka, A., Zhang, J. R., Stepan, G. J., Jin, D., Wong, M. H., Perreira, J. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0560-x · Cited by 154
Muranyi, W., Malkusch, S., Müller, B., Heilemann, M., & Kräusslich, H.-G. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003198 · Cited by 153
Tavassoli, A., Lu, Q., Gam, J., Pan, H., Benkovic, S. J., & Cohen, S. N. (2008) · ACS Chemical Biology · doi:10.1021/cb800193n · Cited by 153
Reactivity of Zinc Finger Cores: Analysis of Protein Packing and Electrostatic Screening
Maynard, A. T., & Covell, D. G. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0011616 · Cited by 152
Matreyek, K., & Engelman, A. (2013) · Viruses · doi:10.3390/v5102483 · Cited by 145
Properties and functions of the nucleocapsid protein in virus assembly
Muriaux, D., & Darlix, J.-L. (2010) · RNA Biology · doi:10.4161/rna.7.6.14065 · Cited by 135
HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus
Malikov, V., da Silva, E. S., Jovasevic, V., Bennett, G., de Souza Aranha Vieira, D. A., Schulte, B., Diaz-Griffero, F., Walsh, D., & Naghavi, M. H. (2015) · Nature Communications · doi:10.1038/ncomms7660 · Cited by 130
Molecular determinants that regulate plasma membrane association of HIV-1 Gag
Chukkapalli, V., & Ono, A. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.015 · Cited by 129 · cited 2×
“The basic patch also has nucleic acid binding properties, and it is thought that the interplay between lipid and RNA binding is critical for a specific interaction with only the plasma membrane [11,48].”
BackgroundAlfadhli, A., Barklis, R. L., & Barklis, E. (2009) · Virology · doi:10.1016/j.virol.2009.02.048 · Cited by 128
On the Role of the SP1 Domain in HIV-1 Particle Assembly: a Molecular Switch?
Datta, S. A. K., Temeselew, L. G., Crist, R. M., Soheilian, F., Kamata, A., Mirro, J., Harvin, D., Nagashima, K., Cachau, R. E., & Rein, A. (2011) · Journal of Virology · doi:10.1128/jvi.00006-11 · Cited by 127 · cited 1×
“Two spacer peptides (SP1 and SP2) flanking the NC domain regulate the kinetics of Gag maturation, and SP1 also provides, as part of the C-terminus of CA, another Gag-Gag multimerization interface [23,24].”
BackgroundLemke, C. T., Titolo, S., von Schwedler, U., Goudreau, N., Mercier, J.-F., Wardrop, E., Faucher, A.-M., Coulombe, R., Banik, S. S. R., Fader, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00493-12 · Cited by 124
Capsid-Dependent Host Factors in HIV-1 Infection
Yamashita, M., & Engelman, A. N. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.04.004 · Cited by 122
Envelope glycoprotein mobility on HIV-1 particles depends on the virus maturation state
Chojnacki, J., Waithe, D., Carravilla, P., Huarte, N., Galiani, S., Enderlein, J., & Eggeling, C. (2017) · Nature Communications · doi:10.1038/s41467-017-00515-6 · Cited by 121
Point Mutations in the HIV-1 Matrix Protein Turn Off the Myristyl Switch
Saad, J. S., Loeliger, E., Luncsford, P. J., Liriano, M., Tai, J., Kim, A., Miller, J. L., Joshi, A., Freed, E. O., & Summers, M. F. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.068 · Cited by 119
Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes
Lamorte, L., Titolo, S., Lemke, C. T., Goudreau, N., Mercier, J.-F., Wardrop, E., Shah, V. B., von Schwedler, U. K., Langelier, C., Banik, S. S. R., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00985-13 · Cited by 119
Quintal, S., de Paula, Q. A., & Farrell, N. P. (2011) · Metallomics · doi:10.1039/c0mt00070a · Cited by 119
Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating
Fernandez, J., Machado, A. K., Lyonnais, S., Chamontin, C., Gärtner, K., Léger, T., Henriquet, C., Garcia, C., Portilho, D. M., Pugnière, M., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0575-6 · Cited by 116
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication
Thenin-Houssier, S., de Vera, I. M. S., Pedró-Rosa, L., Brady, A., Richard, A. S., Konnick, B., Opp, S., Buffone, C., Fuhrmann, J., Kota, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02574-15 · Cited by 112
Turpin, J. A., Song, Y., Inman, J. K., Huang, M., Wallqvist, A., Maynard, A. T., Covell, D. G., Rice, W. G., & Appella, E. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9802517 · Cited by 111
Bharat, T. A. M., Castillo Menendez, L. R., Hagen, W. J. H., Lux, V., Igonet, S., Schorb, M., Schur, F. K. M., Kräusslich, H.-G., & Briggs, J. A. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401455111 · Cited by 107
An Alix Fragment Potently Inhibits HIV-1 Budding
Munshi, U. M., Kim, J., Nagashima, K., Hurley, J. H., & Freed, E. O. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607489200 · Cited by 102
Fader, L. D., Bethell, R. C., Bonneau, P. R., Bös, M., Bousquet, Y., Cordingley, M. G., Coulombe, R., DeRoy, P., Faucher, A., Gagnon, A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.131 · Cited by 102
Akari, H., Fukumori, T., & Adachi, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4891-4893.2000 · Cited by 101
HIV-1 Assembly, Budding, and Maturation
Sundquist, W. I., & Krausslich, H.-G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015420 · Cited by 101
Loo, J. A., Holler, T. P., Sanchez, J. P., Gogliotti, R. D., Maloney, L., & Reily, M. D. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960253w · Cited by 93
Targeting the Viral Nucleocapsid Protein in Anti-HIV-1 Therapy
Mély, Y., de ROCQUIGNY, H., Shvadchak, V. V., Avilov, S., Dong, C., Dietrich, U., & Darlix, J. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708783331603 · Cited by 91
Adamson, C. S., Sakalian, M., Salzwedel, K., & Freed, E. O. (2010) · Retrovirology · doi:10.1186/1742-4690-7-36 · Cited by 87
Nucleocapsid Protein: A Desirable Target for Future Therapies Against HIV-1
Mori, M., Kovalenko, L., Lyonnais, S., Antaki, D., Torbett, B. E., Botta, M., Mirambeau, G., & Mély, Y. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_433 · Cited by 85
Bhattacharya, S., Zhang, H., Debnath, A. K., & Cowburn, D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800048200 · Cited by 85
Van Baelen, K., Salzwedel, K., Rondelez, E., Van Eygen, V., De Vos, S., Verheyen, A., Steegen, K., Verlinden, Y., Allaway, G. P., & Stuyver, L. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01650-08 · Cited by 85
Purdy, M. D., Shi, D., Chrustowicz, J., Hattne, J., Gonen, T., & Yeager, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806806115 · Cited by 84
PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating
Rankovic, S., Ramalho, R., Aiken, C., & Rousso, I. (2018) · Journal of Virology · doi:10.1128/jvi.00845-18 · Cited by 80
Tedbury, P. R., Ablan, S. D., & Freed, E. O. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003739 · Cited by 79
Vlach, J., & Saad, J. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216655110 · Cited by 78
The role of matrix in HIV-1 envelope glycoprotein incorporation
Tedbury, P. R., & Freed, E. O. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.012 · Cited by 77
Anzellotti, A. I., Liu, Q., Bloemink, M. J., Scarsdale, J. N., & Farrell, N. P. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.04.004 · Cited by 76
Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation
Tedbury, P. R., Novikova, M., Ablan, S. D., & Freed, E. O. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516618113 · Cited by 76
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket
Waki, K., Durell, S. R., Soheilian, F., Nagashima, K., Butler, S. L., & Freed, E. O. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002997 · Cited by 71 · cited 2×
“PF-46396 is structurally different from BVM, but both target Gag cleavage at the CA-SP1 site, as indicated by in vitro resistance mutation development [34,35].”
BackgroundFEZ1 Is Recruited to a Conserved Cofactor Site on Capsid to Promote HIV-1 Trafficking
Huang, P.-T., Summers, B. J., Xu, C., Perilla, J. R., Malikov, V., Naghavi, M. H., & Xiong, Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.079 · Cited by 70
Nowicka-Sans, B., Protack, T., Lin, Z., Li, Z., Zhang, S., Sun, Y., Samanta, H. K., Terry, B., Liu, Z., Chen, Y., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02560-15 · Cited by 69
Qian, K., Kuo, R.-Y., Chen, C., Huang, L., Morris-Natschke, S. L., & Lee, K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901782m · Cited by 67
Wu, G., Zalloum, W. A., Meuser, M. E., Jing, L., Kang, D., Chen, C., Tian, Y., Zhang, F., Cocklin, S., Lee, K., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.029 · Cited by 66
Self-citationIdentification of HIV-1 Inhibitors Targeting the Nucleocapsid Protein
Breuer, S., Chang, M. W., Yuan, J., & Torbett, B. E. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201442t · Cited by 64
GGA and Arf Proteins Modulate Retrovirus Assembly and Release
Joshi, A., Garg, H., Nagashima, K., Bonifacino, J. S., & Freed, E. O. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.015 · Cited by 63
Nucleic acid chaperone activity of retroviral Gag proteins
Rein, A. (2010) · RNA Biology · doi:10.4161/rna.7.6.13685 · Cited by 61
Solution Structure and Membrane Interaction of the Cytoplasmic Tail of HIV-1 gp41 Protein
Murphy, R. E., Samal, A. B., Vlach, J., & Saad, J. S. (2017) · Structure · doi:10.1016/j.str.2017.09.010 · Cited by 61
Jiang, X., Wu, G., Zalloum, W. A., Meuser, M. E., Dick, A., Sun, L., Chen, C., Kang, D., Jing, L., Jia, R., et al. (2019) · RSC Advances · doi:10.1039/c9ra05869a · Cited by 61
Self-citationZhou, J., Chen, C. H., & Aiken, C. (2006) · Journal of Virology · doi:10.1128/jvi.01626-06 · Cited by 60
GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds
Singh, K. D., Gallazzi, F., Hill, K. J., Burke, D. H., Lange, M. J., Quinn, T. P., Neogi, U., & Sönnerborg, A. B. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01227 · Cited by 60
Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors
Qian, K., Bori, I. D., Chen, C., Huang, L., & Lee, K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301040s · Cited by 59
Jenkins, L. M. M., Byrd, J. C., Hara, T. J., Srivastava, P., Mazur, S. J., Stahl, S. J., Inman, J. K., Appella, E., Omichinski, J. G., & Legault, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492195 · Cited by 59
Pharmacological intervention of HIV-1 maturation
Wang, D., Lu, W., & Li, F. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.004 · Cited by 58
New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation
Blair, W. S., Cao, J., Fok-Seang, J., Griffin, P., Isaacson, J., Jackson, R. L., Murray, E., Patick, A. K., Peng, Q., Perros, M., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00759-09 · Cited by 56
Tsg101 chaperone function revealed by HIV-1 assembly inhibitors
Strickland, M., Ehrlich, L. S., Watanabe, S., Khan, M., Strub, M.-P., Luan, C.-H., Powell, M. D., Leis, J., Tjandra, N., & Carter, C. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01426-2 · Cited by 55
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors
Urano, E., Ablan, S. D., Mandt, R. E. K., Pauly, G. T., Sigano, D. M., Schneider, J. P., Martin, D. E., Nitz, T. J., Wild, C. T., & Freed, E. O. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02121-15 · Cited by 54
Mechanisms for Env Glycoprotein Acquisition by Retroviruses
Johnson, M. C. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0350 · Cited by 52
Anti-retroviral drugs: current state and development in the next decade
Zhang, X. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.012 · Cited by 51
BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 Capsid
Fricke, T., Buffone, C., Opp, S., Valle-Casuso, J., & Diaz-Griffero, F. (2014) · Retrovirology · doi:10.1186/preaccept-8144459901289378 · Cited by 50
Goudreau, N., Hucke, O., Faucher, A., Grand‐Maître, C., Lepage, O., Bonneau, P. R., Mason, S. W., & Titolo, S. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.022 · Cited by 49
Role of the SP2 Domain and Its Proteolytic Cleavage in HIV-1 Structural Maturation and Infectivity
de Marco, A., Heuser, A.-M., Glass, B., Kräusslich, H.-G., Müller, B., & Briggs, J. A. G. (2012) · Journal of Virology · doi:10.1128/jvi.01704-12 · Cited by 48
Liu, F., Stephen, A. G., Adamson, C. S., Gousset, K., Aman, M. J., Freed, E. O., Fisher, R. J., & Burke, T. R. (2006) · Organic Letters · doi:10.1021/ol0622211 · Cited by 48
Zentner, I., Sierra, L., Fraser, A. K., Maciunas, L. J., Mankowski, M. K., Vinnik, A., Fedichev, P. O., Ptak, R. G., Martín‐García, J., & Cocklin, S. (2013) · ChemMedChem · doi:10.1002/cmdc.201200577 · Cited by 47
Self-citationSingle molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation
Buttler, C. A., Pezeshkian, N., Fernandez, M. V., Aaron, J., Norman, S., Freed, E. O., & van Engelenburg, S. B. (2018) · Nature Communications · doi:10.1038/s41467-018-04220-w · Cited by 47
Pannecouque, C. C., Szafarowicz, B., Volkova, N. N., Bakulev, V. A., Dehaen, W., Mély, Y., & Daelemans, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01671-09 · Cited by 45
Morales-Ramirez, J., Bogner, J. R., Molina, J.-M., Lombaard, J., Dicker, I. B., Stock, D. A., DeGrosky, M., Gartland, M., Pene Dumitrescu, T., Min, S., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0205368 · Cited by 44
Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.
Xu, J. P., Francis, A. C., Meuser, M. E., Mankowski, M. K., Ptak, R. G., Rashad, A. A., Melikyan, G. B., & Cocklin, S. (2018) · PubMed · Cited by 39
Self-citationMori, M., Nucci, A., Lang, M. C. D., Humbert, N., Boudier, C., Debaene, F., Cianférani, S., Catala, M., Schult-Dietrich, P., Dietrich, U., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500316h · Cited by 38
Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain
Martins, A. N., Waheed, A. A., Ablan, S. D., Huang, W., Newton, A., Petropoulos, C. J., Brindeiro, R. D. M., & Freed, E. O. (2015) · Journal of Virology · doi:10.1128/jvi.01640-15 · Cited by 36
Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions
Alfadhli, A., Staubus, A. O., Tedbury, P. R., Novikova, M., Freed, E. O., & Barklis, E. (2019) · Journal of Virology · doi:10.1128/jvi.01079-19 · Cited by 36
Palmer, S. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32835d80af · Cited by 34
Swidorski, J. J., Liu, Z., Sit, S., Chen, J., Chen, Y., Sin, N., Venables, B. L., Parker, D. D., Nowicka-Sans, B., Terry, B., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.019 · Cited by 34
Haffar, O. K., Dubrovsky, L., Lowe, R., Berro, R., Kashanchi, F., Godden, J. W., Vanpouille, C., Bajorath, J., & Bukrinsky, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.13028-13036.2005 · Cited by 33
TSG101: A Novel Anti-HIV-1 Drug Target
Chen, H., Liu, X., Li, Z., Zhan, P., & Clercq, E. D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790514444 · Cited by 32
Liu, Z., Swidorski, J. J., Nowicka-Sans, B., Terry, B., Protack, T., Lin, Z., Samanta, H. K., Zhang, S., Li, Z., Parker, D. D., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.001 · Cited by 32
Resistance to Second-Generation HIV-1 Maturation Inhibitors
Urano, E., Timilsina, U., Kaplan, J. A., Ablan, S. D., Ghimire, D., Pham, P., Kuruppu, N., Mandt, R. E. K., Durell, S. R., Nitz, T. J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.02017-18 · Cited by 32
Lemke, C. T., Titolo, S., Goudreau, N., Faucher, A., Mason, S. W., & Bonneau, P. R. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913006409 · Cited by 31
Vercruysse, T., Basta, B., Dehaen, W., Humbert, N., Balzarini, J. M., Debaene, F., Cianférani, S., Pannecouque, C. C., Mély, Y., & Daelemans, D. (2012) · Retrovirology · doi:10.1186/1742-4690-9-95 · Cited by 31
Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein
Zentner, I., Sierra, L., Maciunas, L. J., Vinnik, A., Fedichev, P. O., Mankowski, M. K., Ptak, R. G., Martín‐García, J., & Cocklin, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.041 · Cited by 29
Self-citationTedbury, P. R., Novikova, M., Alfadhli, A., Hikichi, Y., Kagiampakis, I., KewalRamani, V. N., Barklis, E., & Freed, E. O. (2019) · Journal of Virology · doi:10.1128/jvi.01526-19 · Cited by 28
Analysis of Small Molecule Ligands Targeting the HIV-1 Matrix Protein-RNA Binding Site
Alfadhli, A., McNett, H., Eccles, J. D., Tsagli, S. M., Noviello, C., Sloan, R., López, C. S., Peyton, D. H., & Barklis, E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399865 · Cited by 26
Novikova, M., Adams, L. J., Fontana, J., Gres, A. T., Balasubramaniam, M., Winkler, D. C., Kudchodkar, S. B., Soheilian, F., Sarafianos, S. G., Steven, A. C., et al. (2018) · mBio · doi:10.1128/mbio.01567-18 · Cited by 26
Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer
Xu, J. P., Branson, J. D., Lawrence, R., & Cocklin, S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.087 · Cited by 25
Self-citationTang, J., Jones, S. A., Jeffery, J. L., Miranda, S. R., Galardi, C. M., Irlbeck, D. M., Brown, K. W., McDanal, C. B., Han, N., Gao, D., et al. (2014) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501408010023 · Cited by 23
Wang, W., Zhou, J., Halambage, U. D., Jurado, K. A., Jamin, A. V., Wang, Y., Engelman, A., & Aiken, C. (2017) · Journal of Virology · doi:10.1128/jvi.02155-16 · Cited by 22
Kim, M.-J., Kim, S. H., Park, J. A., Yu, K. L., Jang, S. I., Kim, B., Lee, E. S., & You, J. C. (2015) · Retrovirology · doi:10.1186/s12977-015-0218-9 · Cited by 15
Kim, S. E., Liu, F., Im, Y. J., Stephen, A. G., Fivash, M. J., Waheed, A. A., Freed, E. O., Fisher, R. J., Hurley, J. H., & Burke, T. R. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1002579 · Cited by 14
Toward the “unravelling” of HIV: Host cell factors involved in HIV-1 core uncoating
Rawle, D. J., & Harrich, D. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007270 · Cited by 12
Treatment of Chronic Hepatitis B and Chronic Hepatitis C
Terrault, N. A. (1996) · Reviews in Medical Virology · doi:10.1002/(sici)1099-1654(199612)6:4<187::aid-rmv176>3.0.co;2-f · Cited by 2
Research works printed but not linked: 2
- Tse, W.C., Link, J.O., Mulato, A., Niedziela-Majka, A., Rowe, W., Somoza, J.R., Villasenor, A.G., Yant, S.R., Zhang, J.R., and Zheng, J. (2017, January 13–16). Discovery of Novel Potent HIV Capsid Inhibitors with Long-acting Potential. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
- Yant, S.R., Mulato, A., Stepan, G., Villasenor, A.G., Jin, D., and Margot, N.A. (2019, January 4–7). GS-6207, a potent and selective first-in-class long-acting HIV-1 capsid inhibitor. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
Cited by
Sever, B., Otsuka, M., Fujita, M., & Ciftci, H. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073659 · Cited by 77
Jiang, X., Wu, G., Zalloum, W. A., Meuser, M. E., Dick, A., Sun, L., Chen, C., Kang, D., Jing, L., Jia, R., et al. (2019) · RSC Advances · doi:10.1039/c9ra05869a · Cited by 61
Self-citationZhuang, S., & Torbett, B. E. (2021) · Viruses · doi:10.3390/v13030417 · Cited by 55
The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation
Murphy, R. E., & Saad, J. S. (2020) · Viruses · doi:10.3390/v12050548 · Cited by 30
Xu, S., Sun, L., Dick, A., Zalloum, W. A., Huang, T., Meuser, M. E., Zhang, X., Tao, Y., Cherukupalli, S., Ding, D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113903 · Cited by 28
Self-citation
Metadata
- Authors
- Dick, A., & Cocklin, S.
- Affiliations
- Drexel University (US)
- Corresponding author
- Cocklin, Simon
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-04-07
- Volume
- 25
- Issue
- 7
- Pages
- 1687
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7181048
- OpenAlex
- W3015551811
- Cited by
- 28
- References
- 153
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 1
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NS089435, GM125396)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 Gag polyprotein, capsid protein, matrix protein, antiretroviral drug design, drug resistance, HIV-1 life cycle
- MeSH terms
- Acquired Immunodeficiency Syndrome, Humans, HIV-1, HIV Protease Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, Capsid Proteins, gag Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.